{"id":826,"date":"2025-11-18T13:00:11","date_gmt":"2025-11-18T13:00:11","guid":{"rendered":"https:\/\/wickedsister.evit.com.au\/index.php\/2025\/11\/18\/fda-approves-generic-version-of-vumerity-for-relapsing-ms\/"},"modified":"2025-11-18T13:00:11","modified_gmt":"2025-11-18T13:00:11","slug":"fda-approves-generic-version-of-vumerity-for-relapsing-ms","status":"publish","type":"post","link":"https:\/\/wickedsister.evit.com.au\/index.php\/2025\/11\/18\/fda-approves-generic-version-of-vumerity-for-relapsing-ms\/","title":{"rendered":"FDA approves generic version of Vumerity for relapsing MS"},"content":{"rendered":"<p>Zydus Lifesciences received final approval from the U.S. Food and Drug Administration (FDA) to market a generic version of Vumerity (diroximel fumarate) for adults with relapsing forms of multiple sclerosis (MS) and other conditions. The drug will be sold as 231 mg delayed-release capsules, produced at Zydus\u2019s manufacturing facility in Ahmedabad, India, according to a [&#8230;]<\/p>\n<p>The post <a href=\"https:\/\/multiplesclerosisnewstoday.com\/news-posts\/2025\/11\/18\/fda-approves-generic-version-vumerity-relapsing-ms\/\">FDA approves generic version of Vumerity for relapsing MS<\/a> appeared first on <a href=\"https:\/\/multiplesclerosisnewstoday.com\">Multiple Sclerosis News Today<\/a>.<\/p>\n<p><em>Source: <a href=\"https:\/\/multiplesclerosisnewstoday.com\/news-posts\/2025\/11\/18\/fda-approves-generic-version-vumerity-relapsing-ms\/\" rel=\"nofollow noopener\" target=\"_blank\">multiplesclerosisnewstoday.com<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zydus Lifesciences received final approval from the U.S. Food and Drug Administration (FDA) to market a generic version of Vumerity (diroximel fumarate) for adults with relapsing forms of multiple sclerosis (MS) and other conditions. The drug will be sold as 231 mg delayed-release capsules, produced at Zydus\u2019s manufacturing facility in Ahmedabad, India, according to a&#8230;<\/p>\n","protected":false},"author":0,"featured_media":827,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[11,15,9,8,13,14,12,10],"class_list":["post-826","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-multiple-sclerosis-research","tag-brain-repair","tag-marburg-type-ms","tag-ms","tag-multiple-sclerosis","tag-myelin","tag-neuroregeneration","tag-oligodendrocyte","tag-remyelination"],"_links":{"self":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/826","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=826"}],"version-history":[{"count":0,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/826\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media\/827"}],"wp:attachment":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=826"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=826"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}